Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3Department of Pha...

Full description

Bibliographic Details
Main Authors: Chang HM, Chou PY, Chou CH, Tsai HC
Format: Article
Language:English
Published: Dove Medical Press 2021-11-01
Series:Infection and Drug Resistance
Subjects:
biktarvy
bictegravir
switching
virological failure
viremia
Online Access:https://www.dovepress.com/outcomes-after-switching-to-bicftctaf-in-patients-with-virological-fai-peer-reviewed-fulltext-article-IDR

Internet

https://www.dovepress.com/outcomes-after-switching-to-bicftctaf-in-patients-with-virological-fai-peer-reviewed-fulltext-article-IDR

Similar Items